Redox-responsive EGFR-targeted thiolated gelatin-based delivery system was designed for wt-p53 expressing plasmid or gemcitabine encapsulation and subsequent treatment of pancreatic cancer in subcutaneous tumor bearing SCID mice. Here, TP53 is linked to pancreatic neoplasm.